| Subgroups analysis of segmental sclerosis |
No. of trials |
Hazard ratio
(95% CI) |
P-subgroup
difference |
| Sample size |
>200 |
3 |
1.92 (1.14, 3.25) |
0.42 |
| <200 |
5 |
1.43 (0.89, 2.31) |
| Follow-up |
>7 years |
4 |
2.43 (0.87, 6.73) |
0.31 |
| < 7 years |
4 |
1.39 (0.96, 2.00) |
| Endpoint |
ESRD
Renal failure |
5 |
1.21 (0.87, 1.68) |
0.20 |
| 3 |
2.22 (0.93, 5.35) |
| Adjustment |
Univariate
Multivariate |
4 |
2.70 (1.12, 6.48) |
0.04 |
| 4 |
1.05 (1.01, 1.09) |
| Baseline eGFR |
<80 ml/min per 1.73 m2
>80 ml/min per 1.73 mm2 |
4 |
1.91 (1.01, 3.62) |
0.43 |
| 4 |
1.36 (0.77, 2.40) |
| Percentage of nephrotic syndrome |
100% |
3 |
2.75 (1.22, 6.20) |
0.05 |
| <100% |
5 |
1.16 (0.91, 1.48) |
| Percentage of immunosuppression |
>80% |
5 |
1.56 (0.96, 2.53) |
0.75 |
| <80% |
3 |
1.77 (0.98, 3.19) |
| Country |
North American/Europe |
4 |
1.39 (0.96, 2.00) |
0.31 |
| Asia |
4 |
2.43 (0.87, 6.73) |
|
